Subjecting the medical device user fees to sequestration could hinder the FDA from improving the efficiency of its regulatory process, which in turn could impede the growth of medtech companies, according to this opinion piece. The industry already is facing a new tax to help pay for the health care overhaul and should not "be taxed twice by having the user-fee money made unavailable for improved oversight," this article says.

Related Summaries